Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Intangibles (2022 - 2025)

Cytek Biosciences' Change in Intangibles history spans 4 years, with the latest figure at $32000.0 for Q4 2025.

  • For Q4 2025, Change in Intangibles rose 255.56% year-over-year to $32000.0; the TTM value through Dec 2025 reached $106000.0, down 48.04%, while the annual FY2025 figure was $106000.0, 48.04% down from the prior year.
  • Change in Intangibles reached $32000.0 in Q4 2025 per CTKB's latest filing, up from -$2000.0 in the prior quarter.
  • In the past five years, Change in Intangibles ranged from a high of $148000.0 in Q2 2024 to a low of -$8000.0 in Q3 2024.
  • Average Change in Intangibles over 4 years is $46846.2, with a median of $55000.0 recorded in 2023.
  • Peak YoY movement for Change in Intangibles: crashed 112.7% in 2024, then skyrocketed 255.56% in 2025.
  • A 4-year view of Change in Intangibles shows it stood at $80000.0 in 2022, then dropped by 23.75% to $61000.0 in 2023, then tumbled by 85.25% to $9000.0 in 2024, then surged by 255.56% to $32000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Change in Intangibles are $32000.0 (Q4 2025), -$2000.0 (Q3 2025), and $74000.0 (Q2 2025).